.svg){kind=small}
Authors: Pierpaolo Pellicori MD, John G.F. Cleland MD, PhD, Maria Borentain MD, Jorg Taubel MD, Fraser Graham MB ChB, Javed Khan MB ChB, Dario Bruzzese PhD, Paul Kessler MD, John J.V. McMurray MD, Adriaan A. Voors MD, PhD, Christopher M. O'Connor MD, John R. Teerlink MD, G. Michael Felker MD, MHSIn a recent publication in the European Journal of Heart Failure (November 2023), the impact of cimlanod, a vasodilator, on diuretic response in congestive heart failure patients is explored. Download
-min.jpg)
.jpg)
Latest news
Richmond Pharmacology Appoints Patrick Ramiah as Director of Clinical Project Delivery & Operational Excellence
September 1, 2025
Richmond Pharmacology is delighted to announce the promotion of Patrick Ramiah to the role of Director of Clinical Project Delivery & Operational Excellence, effective from 1 September 2025.
Read moreRichmond Pharmacology Announces Promotion of Dr Priscilla Ochuba to Associate Medical Director
August 1, 2025
Richmond Pharmacology is pleased to announce the promotion of Dr Priscilla Ochuba to Associate Medical Director, effective 1st August 2025.
Read moreEvents
JSCPT 2025
5 – 6 December 2025
Richmond Pharmacology will attend JSCPT 2025 in Tokyo, represented by their leadership team. Topics include early-phase studies, bridging studies between Europe and Asia, gene and RNA-based therapy development, and cross-border collaboration.
View event
